Abstract
Neuroblastoma is one of the most common malignant neoplasms in childhood. The most common clinical presentation of this tumour is abdominal mass. However, affected children may have various clinical presentations as a result of disseminated metastatic disease or associated paraneoplastic syndromes at the time of diagnosis. In this article we have outlined the imaging findings in seven patients with “extra-abdominal” presentation of neuroblastoma and the pitfalls in making the correct diagnosis. The purpose of this pictorial review is to alert the general radiologist to the possible presentations of this common childhood malignancy to derive early detection and diagnosis.
Neuroblastoma is the most common solid extracranial tumour in infants and children. It represents approximately 7% of all cases of childhood cancer and results in about 15% of cancer deaths in children [1]. Neuroblastoma arises from primitive neuroblasts of the embryonic neural crest, and therefore can occur anywhere within the sympathetic nervous system [2]. The most common site of the primary tumour occurs within the abdomen (65%). About half of these tumours arise from the adrenal medulla. Other common sites of neuroblastoma include the neck, chest and pelvis [3].
The classic clinical presentation of neuroblastoma is well recognised by paediatric radiologists [4]; however, medical professionals or radiologists working in local hospitals may not be aware of the atypical manifestations of this tumour. As prompt diagnosis and treatment may help to increase survival rates and minimise irreversible damage, especially to the neural system, it is important for both clinicians and radiologists to be aware of some of the less common manifestations of this tumour.
In this article, we illustrate the “extra-abdominal” clinical presentations and imaging findings of seven cases of abdominal neuroblastoma diagnosed in our hospital, a tertiary Children Cancer Centre in Hong Kong, over the past 10 years.
Case reports
Seven patients were included in this pictorial review (Figure 1–7). All of them had primary neuroblastoma within the abdomen, but the initial clinical presentation was extra-abdominal. Two of them presented with bone pain with non-specific radiographic and MRI findings at the symptomatic joints. Both patients were initially under orthopaedic care with provisional diagnosis of juvenile idiopathic arthropathy and septic arthritis, respectively. Four patients presented with swelling in the head and neck regions: one patient with scalp nodules, two patients with periorbital swelling and one patient with mandibular swelling. These “lumps and bumps” were subsequently found to be bony metastases from abdominal neuroblastoma. One patient presented with diarrhoea and was initially treated for gastroenteritis. This symptom was retrospectively found to be related to the paraneoplastic syndrome of neuroblastoma. Two of the above children subsequently developed lower limb weakness related to intraspinal extension of the abdominal neuroblastoma. The correct diagnosis was first proposed when cord compression was found on urgent MRI examination.
A summary of demographic data, clinical presentation, staging, treatment and outcome of all patients is given in Table 1.
Table 1. Summary table of demographic data, clinical presentation, staging, treatment and outcome of the patients.
Case | Age | Sex | Presenting symptoms | Site of primary tumour | Disease extent/site of metastases | Stage | Treatment and clinical outcome |
1(Figure 1) | 6 years | M | Acute onset of left shoulder pain | Right adrenal | Retroperitoneal lymphadenopathy Widespread bone and bone marrow metastases (left shoulder involving the clavicle, scapula and proximal humerus, lower thoracic and lumbar spine, iliac bones, sacrum, proximal femurs) | IV | Intensive chemotherapy followed by peripheral stem cell transplant |
Died at age 8 years with multiple brain metastases | |||||||
2(Figure 2) | 3 years | M | Left hip pain, limping gait and fever | Left adrenal | Extradural compression of spinal cord at T9/10 Widespread bone metastasis (proximal femoral metaphysis and pelvic ischium), bone marrow, paraspinal and pleural involvement | IV | Intensive chemotherapy followed by peripheral stem cell transplant |
Bony relapse at age 5 years | |||||||
3(Figure 3) | 14 months | F | On and off fever for 2 weeks and several nodules over the scalp | Left adrenal | Left renal, retroperitoneal, pelvic and inguinal nodal metastases, bone metastasis (right parietal skull) | IV | Chemotherapy, tumour debulking and radiotherapy |
In remission. No recurrence at age 2 years 6 months | |||||||
4(Figure 4) | 8 months | M | Diarrhoea for 5 days, followed by progressive lower limb weakness with decrease in movement | Left adrenal | Intraspinal extension and extradural compression of the cord from the level of T10-L1/2 | III | Urgent laminectomy, debulking surgery and chemotherapy |
In remission. No recurrence at age 4 years. Paraplegic with neurogenic bladder. | |||||||
5(Figure 5) | 7 months | F | Watery eye discharge and gradual increase in eye swelling extending into bitemporal region | Right adrenal | Bone metastasis to bilateral orbit and bilateral greater wings of the sphenoid bone | IV | Chemotherapy and resection of right adrenal tumour |
In remission. No recurrence at age 10 years | |||||||
6(Figure 6) | 2 years 6 months | F | Difficulty in walking for 3 weeks. Right submandibular swelling for 1 week. | Left adrenal | Bone metastases (right mandible and left femur) | IV | Chemotherapy, debulking resection of primary tumour, right segmental mandibulectomy, followed by radiotherapy and peripheral stem cell transplant |
Died at age 4 years with multiple brain metastases | |||||||
7(Figure 7) | 1 year 5 months | M | Bilateral periorbital swelling and proptosis | Left adrenal | Liver metastasis. Bony metastasis to bilateral orbits, temporal bones, sphenoid wings and maxillae | IV | Chemotherapy, debulking of primary tumour, radiotherapy and peripheral stem cell transplantation |
Died at age 4 years with multiple brain metastases |
Discussion
The presenting signs and symptoms of neuroblastoma are highly variable with a broad spectrum. They are related to the site of the primary tumour, presence of metastases and any associated paraneoplastic syndromes [2]. A summary of the spectrum of clinical signs is given in Table 2 [5]. Around 40% of patients present with signs and symptoms owing to localised disease. Paraspinal tumours in the thoracic, abdominal and pelvic regions occur in 5–15% of patients, and these can extend into the neural foramina causing symptoms related to compression of nerve roots and the spinal cord [6–8]. In this case series, Cases 4 and 6 presented with bilateral lower limb weakness owing to intraspinal extension of the neuroblastoma causing spinal cord compression. Two major paraneoplastic syndromes are commonly seen in patients with localised tumours. Secretion of vasoactive intestinal peptide can result in diarrhoea [2]; this symptom was present in Case 4 of this series. Diarrhoea usually resolves after tumour removal [9]. Most of the patients with abdominal neuroblastoma in this series had a sizable primary tumour. Medical professionals should be aware of the possible symptoms and signs related to this relatively common paediatric neoplasm. Quick abdominal examination supplemented by ultrasound screening can enable a correct diagnosis and facilitate optimal management of the child.
Table 2. Summary table of clinical presentations [4].
Anatomical site of the primary tumour | |
Head and neck | Unilateral palpable mass, Horners syndrome (ptosis, miosis, anophthalmos, anhydrosis) |
Orbit and eye | Exophthalmoses, periorbital ecchymoses (raccoon eyes), palpable masses, edema of conjunctiva, papilledema, strabismus, anisocoria. Opsoclonus (involuntary rapid eye movements in all directions of gaze) |
Chest | Upper thoracic tumours: dyspnoea, pulmonary infections, dysphagia. Lower thoracic tumours: usually no symptoms |
Abdomen and pelvis | Abdominal mass, Anorexia, vomiting, pain, constipation and urinary retention |
Paraspinal regions | Back pain, paraplegia, weakness, areflexia or hyperreflexia in lower extremities accompanied with muscle atrophy, scoliosis. Bladder and anal sphincter dysfunctions |
Bones | Pain, limping |
Lymph nodes | Enlarged cervical mass |
Non-specific constitutional symptoms |
Anorexia, lethargy, pallor, weight loss, abdominal pain, weakness, irritability |
Paraneolastic syndrome | |
Owing to excessive catecholamine (VMA/HVA) | Sweating, flushing, pallor, headache, palpitation |
Owing to vasoactive intestinal peptides (VIP) | Dehydration, hypokalaemia and abdominal distention, secretory diarrhoea, failure to thrive (Kerner–Morrison syndrome) |
Acute myoclonic encephalopathy (opsoclonus-myoclonus [OM] syndrome) | Opsoclonus (dancing eyes syndrome), myoclonus (irregular jerking of muscles of limbs and trunk) |
Extra-abdominal presentations of neuroblastoma
About 50% of patients present with evidence of haematogenous metastases to distant sites such as cortical bone, bone marrow, liver and non-regional lymph nodes.
Skeletal metastases occur in up to 60% of cases with a variable radiological appearance [1]. Skeletal lesions in long bones may present radiographically as osteolytic focus with or without periosteal reaction, lucent horizontal metaphyseal line or vertical linear radiolucent streaks in the metadiaphysis. Some skeletal lesions may present as a pathological fracture. Vertebral collapse might be seen in spinal metastases while metastases to the cranium often manifest as widening of the cranial suture lines owing to subjacent dural metastases. Early skeletal lesions may be missed when cortical destruction is limited as in Case 1 and 2 of this series. MRI is more sensitive for detection of bony lesion; however, the findings might be misinterpreted as other infective/inflammatory causes that share non-specific MRI features. In Case 1 the patient presented with left shoulder pain and fever. He was initially misdiagnosed with juvenile idiopathic arthropathy as the clinical presentation overlapping with arthritic symptomatology. In Case 2 the patient presented with a limp and left hip pain. His MRI was misinterpreted as septic arthritis owing to the presence of joint effusion, soft-tissue oedema and concurrent fever. Subsequent examination confirmed that their musculoskeletal symptoms were related to bone metastases.
Neuroblastoma also has an unexplained tendency to metastasise to the bony orbit and as a result periorbital ecchymoses (“raccoon eyes”) and proptosis are features of disseminated neuroblastoma [2]. Cases 5 and 7 in this series presented with periorbital swelling and raccoon eyes. Proptosis was also evident in the latter patient. In Case 3, the patient presented with scalp nodules. The diagnosis of bony metastases in the above cases became obvious when bone destruction and characteristic periosteal reaction were demonstrated on CT images.
Imaging algorithms in neuroblastoma
Successful planning of individual patient therapy requires precise delineation of the local extent of the neuroblastoma and evaluation of distant metastases. CT, MRI and bone scintigraphy are the primary imaging modalities used in staging disease in children with neuroblastoma. The imaging protocol might vary from institution to institution. Brodeur et al [10] has published the revised criteria for neuroblastoma diagnostic work up based on experience with the International Neuroblastoma Staging System (INSS) and International Neuroblastoma Response Criteria (INRC). The imaging tests recommended for assessment of the extent of the disease are listed in Table 3. One major modification proposed in Bordeur's paper [10] is that CT scans or MRI (but not ultrasound) are recommended to evaluate the abdomen. It is recommended that three-dimensional measurements of the primary tumour and large metastases should be obtained by CT or MRI to determine response to treatment, while ultrasound may be a useful modality for interim assessments. Recently, MRI has supplemented CT for the staging of neuroblastoma [11–13]. In small series, MRI has also been shown to be more sensitive in the detection of local disease [14, 15]. MRI is better for paraspinal lesions and is essential when assessing intra-g0oraminal extension of the tumour and its potential for cord compression [2]. MRI is also superior to CT for characterising epidural extension, leptomeningeal disease and for the detection of bone marrow metastases [16]. However, many district hospitals may not have the facilities for paediatric MRI, particularly in the age group prevalent for neuroblastoma, in whom general anaesthesia is often required. Contrast-enhanced CT is therefore the most commonly used modality for disease staging for neuroblastoma worldwide. CT alone has been reported to be 82% accurate in revealing tumour extent [10].
Table 3. International guidelines for diagnosis and imaging follow-up [9].
Tumour site | Recommended tests |
Primary tumour | CT and/or MRI scan with 3D measurements; MIBG scan if available |
Metastatic sites | |
Bone marrow | Bilateral posterior iliac crest marrow aspirates and trephine (core) bone marrow biopsies required to exclude marrow involvement. A single positive site documents marrow involvement. Core biopsies must contain at least 1 cm of marrow (excluding cartilage) to be considered adequate |
Bone | MIBG scan; 99Tc scan required if MIBG scan negative or unavailable, and plain radiographs of positive lesions are recommended |
Lymph nodes | Clinical examination (palpable nodes), confirmed histologically. CT scan for non-palpable nodes (3D measurements) |
Abdomen/liver/chest | CT and/or MRI scan with three dimensional measurements. Anteroposterior and lateral chest radiographs. CT/MRI necessary if chest radiograph positive, or if abdominal mass/nodes extend into chest |
3D, three-dimensional; MIBG,18I-metaiodobenzylguanidine.
Metaiodobenzylguanidine (MIBG), which is taken up by tumours derived from the neural crest, has excellent sensitivity (>90%) and near-absolute specificity in the context of neuroblastoma owing to its tumour-specific uptake [17]. A recent study shows that MIBG single photon emission CT (SPECT) bridges the gap between planar MIBG scintigraphy and diagnostic CT [18]. SPECT is particularly useful in cases where there is difficult differential anatomy to distinguish between bowel loops and eventual involved lymph nodes on CT, and in cases when CT reading is impaired by anatomical distortion after surgery or irradiation. SPECT also enhances the diagnostic certainly for small foci, which are overlooked by CT. 111In-diethylenetriaminepentaacetic acid (DTPA)-octreotid scan (somatostatin receptor analogue) yields prognostic information for neuroblastoma [19]. Positive octreotide scintigraphy indicates high level of somatostatic-2 (SST2) receptor gene expression within neuroblastoma and is correlated with a favourable clinical outcome [20]. However, MIBG scinitgraphy is more sensitive than octreotide scintigraphy for detection of neuroblastoma, therefore both studies have a complementary role in initial diagnostic workup [21].
In a review by McHugh and Pritchard [22], the importance of differentiating stage IVS (which has a Stage I/II primary tumour and dissemination limited to the liver, skin and/or bone marrow) and Stage IV (which has metastases to distant lymph nodes, bones, bone marrow, liver and/or other organs) diseases have been emphasised. Several investigators have reported the presence of MIBG scan-negative, bone scan-positive sites of metastatic neuroblastoma [17]. To omit bone scanning may result in incorrect staging in up to 10% of cases. Supplementary bone scintigraphy reportedly increases the accuracy to 97% [10]. Bone scintigraphy has been traditionally used to survey for occult bony metastases [23, 24]. In the setting of confirmed neuroblastoma and multiple or diffuse abnormalities detected on bone scintigraphy, the positive findings should be regarded as highly suggestive of bone metastases even if plain radiography of the abnormal sites is unrevealing. Ideally, MIBG and bone scintigraphy should be done in all children with neuroblastoma at diagnosis to help decide the correct treatment strategy.
Positron emission tomography-CT (PET-CT) has gained importance in staging child cancer. Fluorodeoxyglucose (FDG) PET-CT has the advantage over the standard imaging modalities of characterising tumours both anatomically and metabolically. In a recent study, 113 paired 18-g0luoro-g0DG PET studies and 123I-MIBG scintigraphy were compared for their diagnostic accuracy in neuroblastoma [25]. In general, FDG can better delineate disease extent in the chest, abdomen and pelvis and is superior in depicting Stage I and II neuroblastoma. MIBG is better for detection of bone and marrow metastases and is overall superior in evaluation of Stage IV neuroblastoma, especially during initial chemotherapy. However, in patients with tumours that weakly accumulate 123I-MIBG, PET studies provide important information during staging and at major decision points during therapy, such as before stem cell transplantation or before surgery.
Relative costs and availability of the above imaging modalities and local expertise as well as the physician's preference will continue to influence the imaging protocol in different institutions. In our institution, all children with neuroblastoma undergo multimodality imaging for initial staging: CT/MR (including thorax, abdomen and pelvis +/− brain and neck regions) for delineating the extent of primary tumour, MIBG and bone scintigraphy with SPECT for correlation with CT/MR, and the PET study is optional as the cost is covered by the patient's family. Octreotide scintigraphy is not currently available in our centre so the prognosis of neuroblastoma is determined by both clinical staging and pathological classification (Shimada system) [26].
Conclusion
General radiologists and clinicians should be aware of the unusual clinical presentation of neuroblastoma in children. A quick abdominal examination supplemented by ultrasound screening can enable a correct diagnosis while a standardised imaging algorithm can facilitate optimal management of the child.
References
- 1.David R, Lamki N, Fan S, Singleton EB, Eftekhari F, Shirkhoda A, et al. The many faces of neuroblastoma. Radiographics 1989;9:859–82 [DOI] [PubMed] [Google Scholar]
- 2.Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106–20 [DOI] [PubMed] [Google Scholar]
- 3.De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero DiMontezemolo L, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003;21:1592–601 [DOI] [PubMed] [Google Scholar]
- 4.Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics 2002;22:911–34 [DOI] [PubMed] [Google Scholar]
- 5.Lanzkowsky P. Neuroblastoma. In: Lanzkowsky P, editor. Annual of pediatric hematology and oncology. 4 edn. London: Elsevier Academic Press, 2005::530–2 [Google Scholar]
- 6.Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165–73 [DOI] [PubMed] [Google Scholar]
- 7.Sawada T, Hirayama M, Nakata T, Takeda T, Takasugi N, Mori T, et al. Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group. Lancet 1984;2:271–3 [DOI] [PubMed] [Google Scholar]
- 8.Nishi M, Miyake H, Takeda T, Shimada M, Takasugi N, Sato Y, et al. Effects of the mass screening of neuroblastoma in Sapporo City. Cancer 1987;60:433–6 [DOI] [PubMed] [Google Scholar]
- 9.Kaplan SJ, Holbrook CT, McDaniel HG, Buntain WL, Crist WM. Vasoactive intestinal peptide secreting tumours of childhood. Am J Dis Child 1980;134:21–4 [DOI] [PubMed] [Google Scholar]
- 10.Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466–77 [DOI] [PubMed] [Google Scholar]
- 11.Ng YY, Kingston JE. The role of radiology in the staging of neuroblastoma. Clin Radiol 1993;47:226–35 [DOI] [PubMed] [Google Scholar]
- 12.Siegel MJ, Ishwaran H, Fletcher BD, Meyer JS, Hoffer FA, Jaramillo D, et al. Staging of neuroblastoma at imaging: report of the radiology diagnostic oncology group. Radiology 2002;223:168–75 [DOI] [PubMed] [Google Scholar]
- 13.Pfluger T, Schmied C, Porn U, Leinsinger G, Vollmar C, Dresel S, et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol 2003;181:1115–24 [DOI] [PubMed] [Google Scholar]
- 14.Sofka CM, Semelka RC, Kelekis NL, Worawattanakul S, Chung CJ, Gold S, et al. Magnetic resonance imaging of neuroblastoma using current techniques. Magn Reson Imaging 1999;17:193–8 [DOI] [PubMed] [Google Scholar]
- 15.Tanabe M, Ohnuma N, Iwai J, Yoshida H, Takahashi H, Maie M, et al. Bone marrow metastasis of neuroblastoma analyzed by MRI and its influence on prognosis. Med Pediatr Oncol 1995;24:292–9 [DOI] [PubMed] [Google Scholar]
- 16.Meyer JS, Siegel MJ, Farooqui SO, Jaramillo D, Fletcher BD, Hoffer FA. Which MRI sequence of the spine best reveals bone-marrow metastases of neuroblastoma? Pediatr Radiol 2005;35:778–85 [DOI] [PubMed] [Google Scholar]
- 17.Howman-Giles R, Bernard E, Uren R. Pediatric nuclear oncology. Q J Nucl Med 1997;41:321–35 [PubMed] [Google Scholar]
- 18.Rozovsky K, Koplewitz BZ, Krausz Y, Revel-Vilk S, Weintraub M, Chisin R, et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR Am J Roentgenol 2008;190:1085–90 [DOI] [PubMed] [Google Scholar]
- 19.Schilling FH, Bihl H, Jacobsson H, Ambros PF, Martinsson T, Borgstrom P, et al. Combined (111)In-pentetreotide scintigraphy and (123)I-mIBG scintigraphy in neuroblastoma provides prognostic information. Med Pediatr Oncol 2000;35:688–91 [DOI] [PubMed] [Google Scholar]
- 20.Orlando C, Raggi CC, Bagnoni L, Sestini R, Briganti V, La Cava G, et al. Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium -111-pentetreotide. Med Pediatr Oncol 2001;36:224–6 [DOI] [PubMed] [Google Scholar]
- 21.Pashankar FD, O'Dorisio MS, Menda Y. MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use. J Nucl Med 2005;46 Suppl 1:55S–61S [PubMed] [Google Scholar]
- 22.McHugh K, Pritchard J. Problems in the imaging of three common paediatric solid tumours. Eur J Radiol 2001;37:72–8 [DOI] [PubMed] [Google Scholar]
- 23.Howman-Giles RB, Gilday DL, Ash JM. Radionuclide skeletal survey in neuroblastoma. Radiology 1979;131:497–502 [DOI] [PubMed] [Google Scholar]
- 24.Heisel MA, Miller JH, Reid BS, Siegel SE. Radionuclide bone scan in neuroblastoma. Pediatrics 1983;71:206–9 [PubMed] [Google Scholar]
- 25.Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-g0DG PET in neuroblastoma. J Nucl Med 2009;50:1237–43 [DOI] [PubMed] [Google Scholar]
- 26.Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364–72 [PubMed] [Google Scholar]